Skip to main content
. 2020 Dec 15;14:611278. doi: 10.3389/fnbeh.2020.611278

Table 1.

Clinical data of patients with drug-resistant mesial temporal lobe epilepsy (DR-MTLE).

ID Gender Age (years) Age of seizure onset (years) Duration of epilepsy (years) Frequency of seizures (per month) Side of focus Precipitating factors ASD before surgery
HUM-138 F 37 4 33 75 Left Febrile seizures in childhood PHT/CBZ/VA/ OXC/CLN
HUM-154 F 9 3 6 7 Right Febrile seizures in childhood VA/TOP/CBZ/ PHB/LEV/LAM
HUM-155 M 31 12 19 20 Left Febrile seizures in childhood PHT/VA/CBZ/LAM
HUM- 161 M 19 0.16 19 2 Left Febrile seizures in childhood PHT/VA/CBZ/TOP
HUM-162 M 56 18 38 30 Right Temporal-occipital AVM CBZ/DZP/PHT/ PHB/LEV/VA
HUM-168 M 28 15 13 15 Bilateral TBI and mother with epilepsy CBZ/CLN/LEV
HUM-169 M 46 12 34 15 Right TBI PHT/CBZ
HUM-173 F 46 8 38 2 Right Unknown PHT/OXC
HUM-184 F 28 13 15 16 Bilateral Unknown LAM/VA/CBZ/LEV
HUM-192 M 41 32 9 10 Left Father with epilepsy LAM/VA/CBZ/LEV
HUM-193 F 22 11 11 4 Right Febrile seizures in childhood LAM/VA/LEV/TOP

ASD, antiseizure drugs; AVM, arteriovenous malformation; CBZ, carbamazepine; CLN, clonazepam; F, female; LAM, lamotrigine; LEV, levetiracetam; M, male; OXC, oxcarbazepine; PHB, phenobarbital; PHT, phenytoin; TBI, traumatic brain injury; TOP, topiramate; VA, valproic acid.